oasis 1 oral semaglutide 50 mg obesity nejm 2023 results FDA approves first-ever oral GLP-1RA for obesity and chronic weight management. Meet Wegovy ( semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the 📊 Research Summary: Once-weekly 9-mg

But understanding that Qsymia is not a GLP-1 is important when comparing costs, because you are comparing medications with different effectiveness levels

By activating both GIP and GLP-1 receptors, it helps increase insulin secretion (which lowers blood sugar) and decrease glucagon secretion (which also helps lower blood sugar) in a glucose-dependent manner

J Biol Chem 1996

It contributes valuable benefits in addressing chronic kidney injury prevention and treatment plans

Welcome back to my deep dive on this amazing longevity peptide

However: Wegovy is dosed at a higher level (up to 2.4 mg/week), which may lead to faster or greater weight loss